Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)
Status:
Completed
Trial end date:
2020-07-20
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of filgotinib, when compared
to placebo, in establishing clinical remission defined as Crohn's disease activity index
(CDAI) < 150, at Week 24 in participants with small bowel Crohn's disease (CD). Participants
will have the option to enter a separate long-term extension study if they meet eligibility
requirements.